Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.42)
# 973
Out of 5,008 analysts
499
Total ratings
45.08%
Success rate
5.16%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Reiterates: Neutral | $1 | $1.17 | -14.53% | 18 | Sep 30, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $16.12 | +24.07% | 21 | Sep 18, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $65.49 | +22.16% | 34 | Sep 17, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $30.95 | +48.63% | 25 | Sep 9, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $31 → $34 | $26.44 | +28.59% | 2 | Sep 8, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $16.11 | +117.26% | 23 | Sep 4, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $14 | $8.76 | +59.82% | 18 | Sep 3, 2025 | |
| EVO Evotec SE | Maintains: Buy | $8 → $7 | $3.92 | +78.57% | 10 | Aug 14, 2025 | |
| BHVN Biohaven | Maintains: Buy | $54 → $30 | $15.02 | +99.73% | 15 | Aug 12, 2025 | |
| EOLS Evolus | Maintains: Buy | $27 → $20 | $6.26 | +219.49% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $115 | $52.04 | +120.98% | 25 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $720 → $774 | $797.35 | -2.93% | 40 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $67.89 | +73.81% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $42.50 | +90.59% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.32 | +977.59% | 26 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $39.16 | +35.34% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.71 | +309.36% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $21.00 | +61.90% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $20.57 | -7.63% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.25 | +434.52% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.67 | +217.46% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.86 | +867.74% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $25.21 | +126.10% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $14.35 | +4.53% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.18 | +129.36% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.94 | +38,398.56% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.08 | +825.93% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $186.65 | -2.49% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.55 | +148.34% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $37.62 | -52.15% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $20.07 | -60.14% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $23.62 | +120.15% | 2 | Jun 11, 2019 |
Outlook Therapeutics
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.17
Upside: -14.53%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $16.12
Upside: +24.07%
Protagonist Therapeutics
Sep 17, 2025
Reiterates: Buy
Price Target: $80
Current: $65.49
Upside: +22.16%
Alkermes
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $30.95
Upside: +48.63%
Rapport Therapeutics
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $26.44
Upside: +28.59%
Immunovant
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $16.11
Upside: +117.26%
Rezolute
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $8.76
Upside: +59.82%
Evotec SE
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.92
Upside: +78.57%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $15.02
Upside: +99.73%
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.26
Upside: +219.49%
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $52.04
Upside: +120.98%
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $797.35
Upside: -2.93%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $67.89
Upside: +73.81%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $42.50
Upside: +90.59%
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $2.32
Upside: +977.59%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $39.16
Upside: +35.34%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.71
Upside: +309.36%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $21.00
Upside: +61.90%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $20.57
Upside: -7.63%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.25
Upside: +434.52%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $5.67
Upside: +217.46%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.86
Upside: +867.74%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $25.21
Upside: +126.10%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $14.35
Upside: +4.53%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $2.18
Upside: +129.36%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.94
Upside: +38,398.56%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.08
Upside: +825.93%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $186.65
Upside: -2.49%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.55
Upside: +148.34%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $37.62
Upside: -52.15%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $20.07
Upside: -60.14%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $23.62
Upside: +120.15%